
Nasus Pharma is a clinical-stage pharmaceutical company using a proprietary powder formulation platform for rapid intranasal absorption in acute emergencies.
nasuspharma.comCrawled Nov 11, 2026
Nasal epinephrine delivers epinephrine through the nose to treat anaphylaxis, a medical emergency.
NS003 Ondansetron is Nasus Pharma’s intranasal powder formulation for chemotherapy and post-operative nausea.
NS001 Naloxone is Nasus Pharma’s intranasal powder formulation for rapid opioid overdose reversal.
NS002 is Nasus Pharma’s intranasal powder candidate for treating anaphylaxis.
Dry Powder Formulations in Medicine: How They Work A dry powder inhaler delivers medicine in the form of fine particles
Powder vs Liquid Intranasal Delivery Nasal medicines can be delivered as liquid droplets or dry powder. Both formats offer ways to deliver a substance throu ...
Brendan O'Grady serves as CEO of Nasus Pharma, bringing pharmaceutical industry leadership to its drug delivery solutions.
Isaac Israel serves as a Board Member at Nasus Pharma, bringing expertise in healthcare companies, executive leadership, and corporate strategy.
Meet Joel Brooks, D.O., M.P.H, Advisory Board Member at Nasus Pharma, with expertise in allergy, immunology, anaphylaxis, and clinical research.
Michael S. Blaiss, MD, contributes allergy and immunology expertise to Nasus Pharma’s work on allergic disease management.
Nasus Pharma’s headquarters is located at Yigal Alon 65, Tel Aviv, Israel. Contact via email at info@nasuspharma.com.
Nasus Pharma develops powder-based intranasal therapies using Nasax technology for rapid drug delivery, improved absorption, and emergency treatments.
Nasus Pharma’s Privacy Policy explains how it collects, uses, protects, and manages personal data.
Nasus Pharma’s Terms and Conditions outline website rules, user responsibilities, and legal policies.
Nasus Pharma presents research on **NS002**, its intranasal epinephrine powder for anaphylaxis treatment, at the **ACAAI 2026 Annual Scientific Meeting**. The company, specializing in intranasal pharmaceuticals, highlights clinical-stage findings for this investigational drug. The abstracts will be featured during the upcoming allergy and immunology conference.
Nov 2026ir.nasuspharma.comNews article
Nasus Pharma begins dosing the first patient in a Phase 1 trial of **NS003**, its intranasal formulation of ondansetron. The study evaluates pharmacokinetic properties in humans. Topline results from this first-in-human trial are expected in the fourth quarter of 2026.
Sep 2026ir.nasuspharma.comNews article
Nasus Pharma begins a clinical study to evaluate **NS002**, an intranasal epinephrine powder, as a needle-free alternative to **EpiPen®** for anaphylaxis patients. The trial compares self-administration by patients to administration by healthcare professionals. NS002 aims to address limitations of current injectable treatments.
Sep 2026ir.nasuspharma.comNews article
Nasus Pharma’s Chief Financial Officer, Eyal Rubin, is departing to pursue an opportunity outside the life sciences sector. Rubin remains with the company until **September 18, 2026**, to facilitate a smooth transition. The clinical-stage pharmaceutical firm specializes in intranasal drug development.
Aug 2026ir.nasuspharma.comNews article